androgenetic alopecia
Conditions
Interventions
CGF microneedling:Microneedling was done using a derma roller with needles on all plains of the scalp till erythema/pinpoint bleeding was observed as an endpoint. Following microneedling, CGF was ap
conventional CGF:CGF was injected via 1 mL insulin syringes using the nappage technique in the target area .
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: (1) Patients aged 18 to 45 years, inclusive, with overall good health and a clear diagnosis of AGA; (2) Female patients with severe hair loss classified as Sinclair grades II and III and male patients with severe hair loss classified as Hamilton-Norwood grades II to VI; (3) No local use of hair growth drugs or other local treatments within 3 months prior to treatment; (4) No systemic use of hair growth drugs within 3 months prior to treatment; (5) Clearly understand and agree to the treatment plan and follow-up plan, voluntarily participate, and sign a written informed consent form; (6) Have good compliance and regularly participate in follow-ups; (7) During the study period, willing to maintain the same hairstyle and hair length and not dye or perm the hair.
Exclusion criteria
Exclusion criteria: (1) Other types of hair loss, such as alopecia areata, telogen effluvium, hair loss caused by tinea capitis, syphilitic alopecia, and hair loss due to chemotherapy; (2) Those with severe hypertension, coronary heart disease, diabetes, cranial brain disorders, tumors, etc.; (3) Those with scalp skin diseases that affect the evaluation of therapeutic effects, such as fungal or bacterial infections, severe seborrheic dermatitis, scalp psoriasis, contact dermatitis, severe folliculitis or scalp atrophy, etc.; (4) Those with keloid constitution, abnormal coagulation function, pregnant or lactating women, women in menopause or with menstrual disorders; (5) Those allergic to minoxidil; (6) Those who cannot attend follow-up visits on time; (7) Those deemed unsuitable for participation in this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Terminal hair density difference; | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician's assessment score for clinical improvement.;Patient's self-assessment score for clinical improvement.; | — |
Countries
China
Contacts
Public ContactShen Zhengyu
Department of Dermatology, Shanghai Ninth People’s Hospital
Outcome results
None listed